Impact of oral, selective, allosteric tyrosine kinase 2 inhibitor, deucravacitinib, on psoriasis in patients with active psoriatic arthritis: results from a phase 2 trial

Alice B. Gottlieb; April W. Armstrong; Joseph F. Merola; Andrew Napoli; Miroslawa Nowak; Subhashis Banerjee; Thomas Lehman; Philip J. Mease

doi:10.25251/skin.8.supp.383

Impact of oral, selective, allosteric tyrosine kinase 2 inhibitor, deucravacitinib, on psoriasis in patients with active psoriatic arthritis: results from a phase 2 trial

Alice B. Gottlieb, April W. Armstrong, Joseph F. Merola, Andrew Napoli, Miroslawa Nowak, Subhashis Banerjee, Thomas Lehman, Philip J. Mease

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English (US)
Pages (from-to)	S383
Journal	SKIN: Journal of Cutaneous Medicine
Volume	8
Issue number	2
DOIs	https://doi.org/10.25251/skin.8.supp.383
State	Published - Mar 18 2024

ASJC Scopus subject areas

Dermatology

Access to Document

10.25251/skin.8.supp.383

Cite this

Gottlieb, A. B., Armstrong, A. W., Merola, J. F., Napoli, A., Nowak, M., Banerjee, S., Lehman, T., & Mease, P. J. (2024). Impact of oral, selective, allosteric tyrosine kinase 2 inhibitor, deucravacitinib, on psoriasis in patients with active psoriatic arthritis: results from a phase 2 trial. SKIN: Journal of Cutaneous Medicine, 8(2), S383. https://doi.org/10.25251/skin.8.supp.383

Impact of oral, selective, allosteric tyrosine kinase 2 inhibitor, deucravacitinib, on psoriasis in patients with active psoriatic arthritis: results from a phase 2 trial. / Gottlieb, Alice B.; Armstrong, April W.; Merola, Joseph F. et al.
In: SKIN: Journal of Cutaneous Medicine, Vol. 8, No. 2, 18.03.2024, p. S383.

Research output: Contribution to journal › Comment/debate › peer-review

Gottlieb, AB, Armstrong, AW, Merola, JF, Napoli, A, Nowak, M, Banerjee, S, Lehman, T & Mease, PJ 2024, 'Impact of oral, selective, allosteric tyrosine kinase 2 inhibitor, deucravacitinib, on psoriasis in patients with active psoriatic arthritis: results from a phase 2 trial', SKIN: Journal of Cutaneous Medicine, vol. 8, no. 2, pp. S383. https://doi.org/10.25251/skin.8.supp.383

@article{6fb7c124f8414765b7f775cd1ef6a6ec,

title = "Impact of oral, selective, allosteric tyrosine kinase 2 inhibitor, deucravacitinib, on psoriasis in patients with active psoriatic arthritis: results from a phase 2 trial",

author = "Gottlieb, {Alice B.} and Armstrong, {April W.} and Merola, {Joseph F.} and Andrew Napoli and Miroslawa Nowak and Subhashis Banerjee and Thomas Lehman and Mease, {Philip J.}",

year = "2024",

month = mar,

day = "18",

doi = "10.25251/skin.8.supp.383",

language = "English (US)",

volume = "8",

pages = "S383",

journal = "SKIN: Journal of Cutaneous Medicine",

issn = "2574-1624",

publisher = "National Society for Cutaneous Medicine",

number = "2",

}

TY - JOUR

T1 - Impact of oral, selective, allosteric tyrosine kinase 2 inhibitor, deucravacitinib, on psoriasis in patients with active psoriatic arthritis

T2 - results from a phase 2 trial

AU - Gottlieb, Alice B.

AU - Armstrong, April W.

AU - Merola, Joseph F.

AU - Napoli, Andrew

AU - Nowak, Miroslawa

AU - Banerjee, Subhashis

AU - Lehman, Thomas

AU - Mease, Philip J.

PY - 2024/3/18

Y1 - 2024/3/18

UR - http://www.scopus.com/inward/record.url?scp=85188933323&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85188933323&partnerID=8YFLogxK

U2 - 10.25251/skin.8.supp.383

DO - 10.25251/skin.8.supp.383

M3 - Comment/debate

AN - SCOPUS:85188933323

SN - 2574-1624

VL - 8

SP - S383

JO - SKIN: Journal of Cutaneous Medicine

JF - SKIN: Journal of Cutaneous Medicine

IS - 2

ER -

Impact of oral, selective, allosteric tyrosine kinase 2 inhibitor, deucravacitinib, on psoriasis in patients with active psoriatic arthritis: results from a phase 2 trial

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this